388105-01-9Relevant articles and documents
CC chemokine receptor-3 (CCR3) antagonists: Improving the selectivity of DPC168 by reducing central ring lipophilicity
Pruitt, James R.,Batt, Douglas G.,Wacker, Dean A.,Bostrom, Lori L.,Booker, Shon K.,McLaughlin, Erin,Houghton, Gregory C.,Varnes, Jeffrey G.,Christ, David D.,Covington, Maryanne,Das, Anuk M.,Davies, Paul,Graden, Danielle,Kariv, Ilona,Orlovsky, Yevgeniya,Stowell, Nicole C.,Vaddi, Krishna G.,Wadman, Eric A.,Welch, Patricia K.,Yeleswaram, Swamy,Solomon, Kimberly A.,Newton, Robert C.,Decicco, Carl P.,Carter, Percy H.,Ko, Soo S.
, p. 2992 - 2997 (2008/02/05)
DPC168, a benzylpiperidine-substituted aryl urea CCR3 antagonist evaluated in clinical trials, was a relatively potent inhibitor of the 2D6 isoform of cytochrome P-450 (CYP2D6). Replacement of the cyclohexyl central ring with saturated heterocycles provid